FOLH1 and prostate cancer: PSMA PET/CT is increasingly being utilized for both initial staging and restaging of prostate cancer, including in patients with castration-resistant prostate cancer (CRPC) [13], and for identifying candidates for radioligand therapy with Lu-PSMA.